ARTICLE | Clinical News
StreptAnova: Phase I started
October 5, 2015 7:00 AM UTC
Vaxent began a Canadian Phase I trial to evaluate 3 StreptAnova injections over 6 months in 45 healthy adults. PREVENT has exclusive, worldwide rights from Vaxent to develop and commercialize StreptAn...